DARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy

Shu, Jian; Xia, Kejiang; Luo, Hongliang; Wang, Yang

doi:10.7150/ijms.90611



Theranostics

International Journal of Biological Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Med Sci 2024; 21(3):571-582. doi:10.7150/ijms.90611 This issue Cite

Review

DARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy

Jian Shu^1,2#, Kejiang Xia^3#, Hongliang Luo^1✉, Yang Wang^1✉

1. Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330008, Jiangxi, China.
2. Department of Spleen and Stomach Diseases, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang 332000, Jiangxi, China.
3. Department of Neurosurgery, Yingtan People's Hospital, Yingtan 335000, Jiangxi, China.
^#These two authors contributed equally to this work.

Citation:

Shu J, Xia K, Luo H, Wang Y. DARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy. Int J Med Sci 2024; 21(3):571-582. doi:10.7150/ijms.90611. https://www.medsci.org/v21p0571.htm

Other styles

Abstract

DARS-AS1, short for Aspartyl-tRNA synthetase antisense RNA 1, has emerged as a pivotal player in cancers. Upregulation of this lncRNA is a recurrent phenomenon observed across various cancer types, where it predominantly assumes oncogenic roles, exerting influence on multiple facets of tumor cell biology. This aberrant expression of DARS-AS1 has triggered extensive research investigations, aiming to unravel its roles and clinical values in cancer. In this review, we elucidate the significant correlation between dysregulated DARS-AS1 expression and adverse survival prognoses in cancer patients, drawing from existing literature and pan-cancer analyses from The Cancer Genome Atlas (TCGA). Additionally, we provide comprehensive insights into the diverse functions of DARS-AS1 in various cancers. Our review encompasses the elucidation of the molecular mechanisms, ceRNA networks, functional mediators, and signaling pathways, as well as its involvement in therapy resistance, coupled with the latest advancements in DARS-AS1-related cancer research. These recent updates enrich our comprehensive comprehension of the pivotal role played by DARS-AS1 in cancer, thereby paving the way for future applications of DARS-AS1-targeted strategies in tumor prognosis evaluation and therapeutic interventions. This review furnishes valuable insights to advance the ongoing efforts in combating cancer effectively.

Keywords: LncRNA, DARS-AS1, Tumor biomarker, Biological Functions, Regulatory mechanism

Citation styles

APA

Shu, J., Xia, K., Luo, H., Wang, Y. (2024). DARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy. International Journal of Medical Sciences, 21(3), 571-582. https://doi.org/10.7150/ijms.90611.

ACS

Shu, J.; Xia, K.; Luo, H.; Wang, Y. DARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy. Int. J. Med. Sci. 2024, 21 (3), 571-582. DOI: 10.7150/ijms.90611.

NLM

CSE

Shu J, Xia K, Luo H, Wang Y. 2024. DARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy. Int J Med Sci. 21(3):571-582.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.